CSIR-Institute of Genomics & Integrative Biology, New Delhi, India.
Academy of Scientific & Innovative Research (AcSIR), Ghaziabad, India.
Elife. 2023 Feb 8;12:e77976. doi: 10.7554/eLife.77976.
CRISPR-based diagnostics (CRISPRDx) have improved clinical decision-making, especially during the COVID-19 pandemic, by detecting nucleic acids and identifying variants. This has been accelerated by the discovery of new and engineered CRISPR effectors, which have expanded the portfolio of diagnostic applications to include a broad range of pathogenic and non-pathogenic conditions. However, each diagnostic CRISPR pipeline necessitates customized detection schemes based on the fundamental principles of the Cas protein used, its guide RNA (gRNA) design parameters, and the assay readout. This is especially relevant for variant detection, a low-cost alternative to sequencing-based approaches for which no in silico pipeline for the ready-to-use design of CRISPRDx currently exists. In this manuscript, we fill this lacuna using a unified web server, CriSNPr (CRISPR-based SNP recognition), which provides the user with the opportunity to de novo design gRNAs based on six CRISPRDx proteins of choice (/enCas9, Cas13a, Cas12a, Cas12b, and Cas14a) and query for ready-to-use oligonucleotide sequences for validation on relevant samples. Furthermore, we provide a database of curated pre-designed gRNAs as well as target/off-target for all human and SARS-CoV-2 variants reported thus far. CriSNPr has been validated on multiple Cas proteins, demonstrating its broad and immediate applicability across multiple detection platforms. CriSNPr can be found at http://crisnpr.igib.res.in/.
基于 CRISPR 的诊断 (CRISPRDx) 通过检测核酸和识别变体,改善了临床决策,尤其是在 COVID-19 大流行期间。这得益于新的和工程化的 CRISPR 效应物的发现,这些效应物扩展了诊断应用的组合,包括广泛的致病和非致病条件。然而,每个诊断性的 CRISPR 管道都需要根据所使用的 Cas 蛋白、其引导 RNA (gRNA) 设计参数和检测读数的基本原理,定制检测方案。对于变体检测来说,这一点尤为重要,因为与基于测序的方法相比,变体检测是一种低成本的替代方法,目前还没有现成的用于 CRISPRDx 设计的计算管道。在本文中,我们使用统一的网络服务器 CriSNPr (基于 CRISPR 的 SNP 识别) 填补了这一空白,该服务器为用户提供了基于六个 CRISPRDx 蛋白 (/enCas9、Cas13a、Cas12a、Cas12b 和 Cas14a) 从头设计 gRNA 的机会,并查询可用于在相关样本上进行验证的即用型寡核苷酸序列。此外,我们还提供了一个经编辑的预设计 gRNA 数据库,以及迄今为止报告的所有人类和 SARS-CoV-2 变体的靶/脱靶信息。CriSNPr 已经在多种 Cas 蛋白上进行了验证,证明了它在多个检测平台上具有广泛的适用性。CriSNPr 可以在 http://crisnpr.igib.res.in/ 找到。